secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2026-08-11T20:05:23+00:00
Accession:  0001104659-26-094041
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q2 2026 net loss $0.11/share; FDA clears IND for rexaceract Phase 2
--------------------------------------------------------------------------------

- Net loss per share $0.11 (basic/diluted) vs $0.19 in Q2 2025; cash $13.1M at June 30, 2026.
- FDA accepted IND for rexaceract (GT-02287); Phase 2 in Parkinson's expected to start Q3 2026.
- R&D expenses fell to $2.1M from $2.8M; G&A rose to $2.5M from $2.3M year-over-year.
- Phase 1b final results due Q4 2026; 14 of 16 extension participants completed Day 270.
- Promoted Joanne Taylor to CSO and Terenzio Ignoni to COO; GT-04686 indication expected by year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/0001104659-26-094041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465926094041/ganx-20260811x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer